Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis ; volume:7 ; number:1 ; day:2 ; month:8 ; year:2017 ; pages:1-8 ; date:12.2017
Scientific reports ; 7, Heft 1 (2.8.2017), 1-8, 12.2017
- Creator
-
ter Veer, Emil
Ngai, Lok Lam
Valkenhoef, Gert van
Mohammad, Nadia Haj
Anderegg, Maarten C. J.
van Oijen, Martijn G. H.
van Laarhoven, Hanneke W. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-07750-3
- URN
-
urn:nbn:de:101:1-2019102013210108559366
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- ter Veer, Emil
- Ngai, Lok Lam
- Valkenhoef, Gert van
- Mohammad, Nadia Haj
- Anderegg, Maarten C. J.
- van Oijen, Martijn G. H.
- van Laarhoven, Hanneke W. M.
- SpringerLink (Online service)
Other Objects (12)
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial